Ascendiant Capital Markets lifted its 12-month price target on IGC Pharma (IGC) to $6.00 per share from $5.50 on August 28, 2026, while maintaining its BUY rating. The target progression documented in igcpharma.com releases runs $4.75 to $5.25 on April 8, to $5.50 on June 9, and to $6.00 on August 28.
The immediate catalyst is enrollment progress in IGC's Phase 2 CALMA trial, which is evaluating IGC-AD1 for agitation associated with Alzheimer's dementia. According to the company's news release filed August 28, 2026, the trial has achieved its previously disclosed 146-patient baseline randomization target and now sits within six additional randomizations of expected enrollment closure. Ascendiant identifies the anticipated release of topline clinical data in Q4 2026 as a potential strong catalyst for the stock, per the same release.
The research firm said it continues to view IGC's valuation as attractive relative to its potential opportunity, with the revised $6.00 target based on a net present value analysis, per the press release reprinted on openPR.com dated September 1, 2026. Ascendiant also cited the company's expanding AI-enabled Alzheimer's programs as part of its rationale, while acknowledging the risks inherent in clinical-stage biotechnology development.
Beyond CALMA, IGC's pipeline includes TGR-63, which targets amyloid plaques, alongside early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions, per igcpharma.com (May 19, 2026).
CEO Ram Mukunda, in the Q1 2026 earnings release dated May 19, 2026, described the company's operational posture: "During the first quarter, we continued to execute against our core priorities by advancing CALMA, expanding our clinical site network, and strengthening the AI and intellectual property components of our Alzheimer's strategy with disciplined capital allocation."
On the financial side, IGC reported revenue of $869 thousand for the nine-month period ended December 31, 2025, which the company attributed to a planned transition away from white-label manufacturing toward its core pharmaceutical and AI assets, per accessnewswire.com. The company completed a capital raise announced January 5, 2026, described as supporting disciplined clinical execution in the CALMA trial; specific amounts were not disclosed in sources accessed. Share count and current cash position were not available in sources reviewed for this article.
The August 28 action lands on a softer macro tape. As of September 1, 2026, U.S. equity futures are under pressure — Dow futures down 335 points (0.6%), S&P 500 futures off 0.6%, and Nasdaq-100 futures pulling back 1.2%, per FX.co — with traders raising the probability of a Fed rate hike at the September meeting to 65%, up from 34% before Kevin Warsh's Jackson Hole speech.
Ascendiant's three documented target raises — April 8 to $5.25, June 9 to $5.50, August 28 to $6.00 — have each followed disclosed trial milestones, per the igcpharma.com release series. The firm identifies the topline CALMA data readout, which it describes as a potential strong catalyst, as the next disclosed milestone for the program.